866-997-4948(US-Canada Toll Free)

Metastatic Ovarian Cancer - Pipeline Review, H1 2016

Published By :

Global Markets Direct

Published Date : Apr 2016

Category :

Ovarian Cancer

No. of Pages : 87 Pages

Metastatic Ovarian Cancer - Pipeline Review, H1 2016

Summary

Global Markets Directs, Metastatic Ovarian Cancer - Pipeline Review, H1 2016, provides an overview of the Metastatic Ovarian Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Metastatic Ovarian Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Ovarian Cancer and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Metastatic Ovarian Cancer
- The report reviews pipeline therapeutics for Metastatic Ovarian Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Metastatic Ovarian Cancer therapeutics and enlists all their major and minor projects
- The report assesses Metastatic Ovarian Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Metastatic Ovarian Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Metastatic Ovarian Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Metastatic Ovarian Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Metastatic Ovarian Cancer Overview 8
Therapeutics Development 9
Pipeline Products for Metastatic Ovarian Cancer Overview 9
Pipeline Products for Metastatic Ovarian Cancer Comparative Analysis 10
Metastatic Ovarian Cancer Therapeutics under Development by Companies 11
Metastatic Ovarian Cancer Therapeutics under Investigation by Universities/Institutes 12
Metastatic Ovarian Cancer Pipeline Products Glance 13
Clinical Stage Products 13
Early Stage Products 14
Metastatic Ovarian Cancer Products under Development by Companies 15
Metastatic Ovarian Cancer Products under Investigation by Universities/Institutes 16
Metastatic Ovarian Cancer Companies Involved in Therapeutics Development 17
Cellceutix Corporation 17
Eisai Co., Ltd. 18
Eli Lilly and Company 19
F. Hoffmann-La Roche Ltd. 20
Immune Design Corp. 21
Millennium Pharmaceuticals, Inc. 22
MolMed S.p.A. 23
Natco Pharma Limited 24
Northwest Biotherapeutics, Inc. 25
Sumitomo Dainippon Pharma Co., Ltd. 26
VG Life Sciences, Inc. 27
Metastatic Ovarian Cancer Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Combination Products 29
Assessment by Target 30
Assessment by Mechanism of Action 32
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
CMB-305 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
DCVax-Direct - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
E-7449 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
emactuzumab - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
G-305 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
hydroxychloroquine + sorafenib tosylate - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
KM-3174 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
LV-305 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
LY-2780301 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
NGR-hTNF - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
NRCAN-019 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
orteronel - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
OS-2966 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
SM-276001 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Vaccine for Oncology - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Metastatic Ovarian Cancer Recent Pipeline Updates 64
Metastatic Ovarian Cancer - Dormant Projects 83
Metastatic Ovarian Cancer Discontinued Products 84
Metastatic Ovarian Cancer Product Development Milestones 85
Featured News & Press Releases 85
Jun 22, 2015: VG Life Sciences Granted Combination Cancer Drug Patent 85
Appendix 86
Methodology 86
Coverage 86
Secondary Research 86
Primary Research 86
Expert Panel Validation 86
Contact Us 86
Disclaimer 87

List of Tables
Number of Products under Development for Metastatic Ovarian Cancer, H1 2016 9
Number of Products under Development for Metastatic Ovarian Cancer Comparative Analysis, H1 2016 10
Number of Products under Development by Companies, H1 2016 11
Number of Products under Investigation by Universities/Institutes, H1 2016 12
Comparative Analysis by Clinical Stage Development, H1 2016 13
Comparative Analysis by Early Stage Development, H1 2016 14
Products under Development by Companies, H1 2016 15
Products under Investigation by Universities/Institutes, H1 2016 16
Metastatic Ovarian Cancer Pipeline by Cellceutix Corporation, H1 2016 17
Metastatic Ovarian Cancer Pipeline by Eisai Co., Ltd., H1 2016 18
Metastatic Ovarian Cancer Pipeline by Eli Lilly and Company, H1 2016 19
Metastatic Ovarian Cancer Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 20
Metastatic Ovarian Cancer Pipeline by Immune Design Corp., H1 2016 21
Metastatic Ovarian Cancer Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 22
Metastatic Ovarian Cancer Pipeline by MolMed S.p.A., H1 2016 23
Metastatic Ovarian Cancer Pipeline by Natco Pharma Limited, H1 2016 24
Metastatic Ovarian Cancer Pipeline by Northwest Biotherapeutics, Inc., H1 2016 25
Metastatic Ovarian Cancer Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016 26
Metastatic Ovarian Cancer Pipeline by VG Life Sciences, Inc., H1 2016 27
Assessment by Monotherapy Products, H1 2016 28
Assessment by Combination Products, H1 2016 29
Number of Products by Stage and Target, H1 2016 31
Number of Products by Stage and Mechanism of Action, H1 2016 33
Number of Products by Stage and Route of Administration, H1 2016 35
Number of Products by Stage and Molecule Type, H1 2016 37
Metastatic Ovarian Cancer Therapeutics Recent Pipeline Updates, H1 2016 64
Metastatic Ovarian Cancer Dormant Projects, H1 2016 83
Metastatic Ovarian Cancer Discontinued Products, H1 2016 84

List of Figures
Number of Products under Development for Metastatic Ovarian Cancer, H1 2016 9
Number of Products under Development for Metastatic Ovarian Cancer Comparative Analysis, H1 2016 10
Number of Products under Development by Companies, H1 2016 11
Comparative Analysis by Clinical Stage Development, H1 2016 13
Assessment by Monotherapy Products, H1 2016 28
Number of Products by Top 10 Targets, H1 2016 30
Number of Products by Stage and Top 10 Targets, H1 2016 30
Number of Products by Top 10 Mechanism of Actions, H1 2016 32
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 32
Number of Products by Routes of Administration, H1 2016 34
Number of Products by Stage and Routes of Administration, H1 2016 34
Number of Products by Molecule Types, H1 2016 36
Number of Products by Stage and Molecule Types, H1 2016 36

List of Table

NA

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *